BCL2A1

Bcl-2-related protein A1 · Q16548 · BCL2A1 on Sugi Atlas →

12,566 patent compounds predicted against BCL2A1, 6,568 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
(S)-1',6,6',7,7'-Hexahydroxy-3,3'-Dimethyl-N5-((S)-2-Phenylpropyl)-N5'-((S)-2-Phenylpropyl)-2,2'-Binaphthyl-5,5'-Dicarboxamide (Atropisomeric Mix) (SCHEMBL2757182)	1.00	11/20
(S)-1',6,6',7,7'-Hexahydroxy-3,3'-Dimethyl-N5-((S)-2-Phenylpropyl)-N5'-((S)-2-Phenylpropyl)-2,2'-Binaphthyl-5,5'-Dicarboxamide (Atropisomeric Mix) (SCHEMBL2757198)	1.00	11/20
(S)-1',6,6',7,7'-Hexahydroxy-3,3'-Dimethyl-N5-((S)-2-Phenylpropyl)-N5'-((S)-2-Phenylpropyl)-2,2'-Binaphthyl-5,5'-Dicarboxamide (Atropisomeric Mix) (SCHEMBL2757199)	1.00	11/20
SCHEMBL2757178	0.83	11/20
SCHEMBL2757181	0.83	11/20
SCHEMBL2757197	0.73	11/20
SCHEMBL635910	0.59	10/20
SCHEMBL353855	0.65	9/20
SCHEMBL2528280	0.61	9/20
SCHEMBL354620	0.60	9/20
SCHEMBL354329	0.60	9/20
SCHEMBL352771	0.60	9/20
SCHEMBL352976	0.59	9/20
SCHEMBL353588	0.55	9/20
SCHEMBL354989	0.53	9/20
SCHEMBL355129	0.51	9/20
SCHEMBL354750	0.49	9/20
SCHEMBL353531	0.48	9/20
SCHEMBL353267	0.46	9/20
SCHEMBL2532052	1.00	8/20

Clinical trials — most relevant to BCL2A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer	PHASE4	UNKNOWN
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia	PHASE3	COMPLETED
A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide)	PHASE2/PHASE3	COMPLETED
Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)	PHASE3	UNKNOWN
Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML	PHASE3	UNKNOWN
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme	PHASE2	COMPLETED
Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma	PHASE1/PHASE2	WITHDRAWN
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant	PHASE1/PHASE2	RECRUITING
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma	PHASE2	RECRUITING
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia	PHASE2	ACTIVE_NOT_RECRUITING
Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer	PHASE2	COMPLETED
Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission	PHASE2	ACTIVE_NOT_RECRUITING
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma	PHASE2	COMPLETED
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma	PHASE2	COMPLETED
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS	PHASE1	RECRUITING
Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	PHASE1	COMPLETED
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer	PHASE1	COMPLETED
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN	PHASE1	ACTIVE_NOT_RECRUITING
Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	PHASE1	COMPLETED
Safe Accelerated Venetoclax Escalation in CLL	PHASE1	ACTIVE_NOT_RECRUITING
Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer	PHASE1	WITHDRAWN
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects	PHASE1	COMPLETED
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.	nan	RECRUITING
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia	nan	COMPLETED
The Effect of TRA-8 on Ovarian Cancer Tissue	nan	COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Dietary Intervention With High Phenolic EVOO in CLL	nan	COMPLETED
Smoking Influence on Apoptosis in Periodontitis	nan	COMPLETED
Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a BCL2A1 binder may also engage these)

Protein	Name	Similarity
Q3C2I0	—	1.000	Q3C2I0 →
Q08ED0	—	1.000	Q08ED0 →
Q07818	—	0.996	Q07818 →
Q07440	—	0.994	Q07440 →
P41957	—	0.994	P41957 →
Q09562	—	0.992	Q09562 →
Q9VEZ5	—	0.990	Q9VEZ5 →
O36423	—	0.989	O36423 →
Q5TBC7	—	0.989	Q5TBC7 →
Q9BDJ7	—	0.989	Q9BDJ7 →
Q9LSP8	—	0.989	Q9LSP8 →
Q11106	—	0.989	Q11106 →
A7YDW0	—	0.988	A7YDW0 →
Q01001	—	0.988	Q01001 →
F1QYC4	—	0.988	F1QYC4 →
Q9JHB9	—	0.988	Q9JHB9 →
O45460	—	0.988	O45460 →
Q06318	—	0.988	Q06318 →
Q967U1	—	0.988	Q967U1 →
Q15573	—	0.988	Q15573 →
Q61T02	—	0.987	Q61T02 →
Q9FIN7	—	0.987	Q9FIN7 →
Q99M66	—	0.987	Q99M66 →
Q7T047	—	0.987	Q7T047 →
Q9VPN2	—	0.987	Q9VPN2 →
P0CX12	—	0.987	P0CX12 →
Q24592	—	0.987	Q24592 →
Q9DDT2	—	0.987	Q9DDT2 →
B6K0N7	—	0.987	B6K0N7 →
Q9VXD6	—	0.987	Q9VXD6 →